Johann de Bono

Professor Johann de Bono is a world-leading clinician-scientist at The Institute of Cancer Research (ICR), an independent college of the University of London, and the Royal Marsden Hospital (RMH). He serves as Head of the Division of Clinical Studies and co-founded/leads the Royal Marsden Drug Development Unit and ICR/RMH Experimental Cancer Medicine Centre team. His research focuses on prostate cancer, with groundbreaking work in biomarker-driven clinical trials, DNA repair defects, and targeted therapies.

• Developed PARP inhibitors (talazoparib, niraparib, olaparib) for advanced prostate cancer
• Transformed international guidelines for germline testing in prostate cancer
• Established molecular stratification frameworks for prostate cancer treatment

His clinical trials revolutionized prostate cancer care, with key contributions to abiraterone, cabazitaxel, enzalutamide, and lutetium PSMA therapies. Publications span top-tier journals including Nature, Science, Cell, NEJM, and The Lancet.

• 2020 - Elected Fellow of the Royal Society of Biology
• 2018 - AACR Joseph H. Burchenal Memorial Award
• 2016 - Regius Professor of Cancer Research
• 2012 - AACR Team Science Award
• 2011 - ESMO Award

He founded and leads the RM Prostate Cancer Targeted Therapy Group team, with a research focus on genomic landscape mapping of advanced prostate cancer and circulating biomarker applications.